ClearStar integration with Abbott Laboratories

20 June 2018

ClearStar, Inc.

("ClearStar" or the "Company")

ClearStar expands medical testing with Abbott Laboratories integration

Mobile drug and clinical testing services now available at over 9,500 locations

ClearStar (AIM: CLSU), the technology and service provider to the background check industry, announces that its ClearMD mobile drug testing solution is now integrated with Abbott Laboratories (formerly Alere), a leading global provider of healthcare diagnostics. This significantly expands the number of test collection sites where ClearStar's mobile solution for medical test ordering can be used. In addition to the Company's existing integrations with LabCorp and Quest Diagnostics, ClearStar is now the only provider offering paperless medical screening with a fully customisable user platform across all three of the major laboratories in the US.

The Company's ClearMD medical management solution streamlines the medical test ordering and review process and helps to eliminate error through using a paperless chain of custody software. Orders can be placed in the office or on-the-go with an app optimised for both desktop and mobile devices and that enables e-signature consent. It also includes features such as real-time status updates, built-in reminders and a mobile wallet pass that auto-loads when the employee or candidate is near a collection site. The ClearStar platform is also fully customisable to be able to meet the exact client requirements and preferences to ensure the optimum candidate experience, and further streamline the process.

Abbott Laboratories is a leading provider of drug and clinical laboratory services, offering collections at over 4,500 locations across the US. The addition of the Abbott Laboratories sites doubles the number of locations where an employee or candidate can utilise ClearMD and expands ClearStar's coverage, particularly in rural areas. Abbott Laboratories also has a substantial - and growing - international footprint, offering the Company's clients the opportunity to expand their drug screening program to accommodate global hires.

By broadening the number of test collection sites, ClearStar is not only expanding the services it offers, but enhancing the convenience for employees by offering a greater choice of location, which also assists employers by increasing the speed of the process. In addition, ClearStar expects to benefit from the economies of scale associated with engaging multiple large suppliers.

Robert Vale, CEO of ClearStar, commented: "We are very proud to have achieved this integration with Abbott Laboratories, which makes ClearStar the only provider of paperless medical testing with a fully customisable user platform that is integrated with all three major US labs. By increasing the number of medical test sites available through our smartphone-enabled ClearMD, we can provide a better experience for the employee or candidate by offering more choice and less hassle as well as benefit the employer by getting their employee to work quicker.

"This integration, which is the result of substantial efforts by, and the expertise of, our IT engineers, further enhances our competitive position in this market. We hope to leverage this as we continue to receive increasing demand driven by the strength of our differentiated offer in an ever-more mobile society along with changes such as the deregulation of recreational drug use. As a result, we look forward to delivering even greater growth in our medical information services."

Enquiries

About ClearStar

ClearStar, Inc. is a leading and trusted background check technology, medical screening, strategic services, and decision-making information provider to employers and background screening companies.

A seven-time Inc. 5000 honouree and founding member of the National Association of Professional Background Screeners, ClearStar has provided innovative technology solutions to businesses in the human capital management industry from its corporate offices in Alpharetta, Georgia since 1995. For more information about ClearStar, please visit: www.clearstar.net.

The information communicated in this announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No. 596/2014.